The GLP-1 Industry Boom: Market Size in India & Globally and Private Market Excitement

GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed to improve blood sugar control in type 2 diabetes, but they have surged in popularity after demonstrating remarkable weight-loss effects. Since the first FDA approval of a GLP-1 drug (Novo Nordisk’s semaglutide, branded Wegovy) for obesity in 2021, this drug class has transformed into a blockbuster market spanning both diabetes and obesity care. This dual role is driving explosive growth in the GLP-1 industry worldwide, with significant implications for global and Indian markets, and has caught the keen attention of venture capital and private equity investors.

Global GLP-1 Market: Explosive Growth and Projections

The global market for GLP-1 receptor agonist drugs has expanded dramatically, fueled by rising diabetes prevalence and a new wave of demand for obesity treatment. In 2024, the global GLP-1 market was estimated around $50–53 billion in annual sales. This represents a huge jump from just a few years prior, reflecting the rapid uptake of drugs like semaglutide (brand names Ozempic® for diabetes and Wegovy® for weight loss) and liraglutide (Saxenda®) across major markets. Growth is expected to accelerate further as more patients adopt these medications for weight management. Analysts project global GLP-1 drug revenues could reach $126–157 billion by the end of the decade (around 2029–2030). For example, UBS estimates roughly 40 million people could be on GLP-1 therapies by 2029, translating to about $126 billion in sales by 2029 (a stunning ~30% CAGR from 2023). Other market forecasts similarly see annual sales approaching $150+ billion in the early 2030s, underscoring how GLP-1 drugs are becoming one of the largest pharmaceutical segments worldwide.

Several factors are driving this explosive global growth. Skyrocketing rates of obesity and type-2 diabetes are expanding the patient pool for GLP-1 therapies. It’s estimated that over 2.3 billion people worldwide are now overweight or obese, and over 90% of type-2 diabetics are overweight. This creates enormous demand for effective treatments that address both conditions. GLP-1 drugs uniquely tackle both blood sugar control and weight loss, making them highly attractive for patients with metabolic diseases. Their high efficacy (often 10–15% body weight reduction in obesity trials) and additional health benefits (like lower cardiovascular risk) have further boosted uptake. Consequently, the GLP-1 class has become a focus of global healthcare innovation and spending. In 2024, North America (especially the U.S.) accounted for nearly 78% of global GLP-1 revenue, thanks to early adoption and higher medication costs in those markets. However, other regions are catching up quickly – Asia-Pacific is the fastest-growing market for GLP-1 therapies as awareness and access improve.

Novo Nordisk and Eli Lilly – the makers of Wegovy/Ozempic and Mounjaro® (tirzepatide) respectively – currently dominate this space, controlling almost the entire market share. Together these two firms hold over 90% of the GLP-1 market today. Their revenues have surged (Novo Nordisk briefly became Europe’s most valuable company in 2023 due to GLP-1 sales) and they continue to invest heavily in expanding production. Nonetheless, the competitive landscape is poised to broaden: other pharmaceutical players are entering with new GLP-1 analogs or combination therapies, and by 2030 analysts expect up to ~15% of the market could be captured by new entrants. This intense demand has even led to temporary supply shortages as manufacturers race to scale up production. Overall, the global GLP-1 industry’s trajectory suggests it is on track to become a hundreds-of-billions dollar market within the next decade, revolutionizing treatment paradigms for metabolic disorders.

India’s GLP-1 Market: Small Base, Sky-High Growth

In India, the GLP-1 market is at a nascent stage but is expanding at one of the fastest rates in the world. Annual sales of GLP-1 agonist drugs in India were only around $100–115 million in 2023–2024, a tiny fraction of the global market. This small base is partly due to historically limited use – GLP-1 injections have been relatively expensive and primarily prescribed for diabetes in a subset of patients. However, the landscape is changing rapidly. With India facing a dual epidemic of diabetes and obesity, there is surging interest in these medications’ benefits. The country has over 74 million adults living with diabetes, and prevalence is rising steadily; by 2050, as many as 185 million Indians could have diabetes if current trends continue. Obesity rates are climbing as well (projected to reach ~11% of Indian adults by 2035). These health challenges are driving physicians and patients to seek more effective treatments, putting GLP-1 drugs in the spotlight as a promising solution.

Reflecting this, market projections for India are remarkably high. From roughly $110 million in 2024, India’s GLP-1 drug revenues are expected to grow to about $579 million by 2030. In other words, the Indian market could increase 5–6x in size within the next 6–7 years, implying a ~27–34% compound annual growth rate – far above global averages. Analysts anticipate continued strong growth beyond 2030 as well; one report forecasts ~24.7% CAGR through 2034 for India’s GLP-1 sector. This would position India as an important emerging market for GLP-1 therapies in the Asia-Pacific region. However, it’s worth noting that even with such rapid growth, India would still account for only a few tenths of a percent of the global GLP-1 sales by 2030 (India comprised ~0.3% of the world market in 2023). The upside potential is huge if barriers can be overcome.

Several factors will influence how quickly GLP-1 adoption accelerates in India. Affordability and access are key challenges – these drugs can cost hundreds of dollars per month internationally. In India, even with expected price reductions from local generic versions, cost remains a concern for many patients. Only a small affluent segment of the population can comfortably pay out-of-pocket for brand-name GLP-1 treatments today. To improve access, government and industry initiatives are underway. For instance, India plans to offer incentives for domestic manufacturing of GLP-1 drugs by 2026 (via Production-Linked Incentive schemes), which could lower costs and reduce reliance on imports. Equally important, the patents on major GLP-1 drugs are nearing expiry: Novo Nordisk’s patents on semaglutide (Ozempic/Wegovy) will expire around 2026, opening the door for Indian pharmaceutical companies to launch generic GLP-1 formulations . In fact, several Indian pharma firms are already preparing GLP-1 products. For example, Glenmark launched a generic liraglutide injection in 2024 . Cipla and Dr. Reddy’s are working on off-patent GLP-1 opportunities, Biocon has filed regulatory submissions for its GLP-1 candidates, and Sun Pharma is developing a novel GLP-1 drug now in Phase 2 trials . Meanwhile, Eli Lilly plans to introduce its new GLP-1 drug Mounjaro (tirzepatide) in India by 2025 . This rising competition and local production should improve availability and gradually bring down prices, which will be crucial for unlocking the full market potential in India.

On the demand side, growing clinical awareness of GLP-1 benefits for obesity is boosting interest. Indian doctors traditionally used GLP-1 RAs mainly for diabetes patients, but with global evidence of ~15% weight loss in trials, specialists are now considering them for high-BMI patients as well. Early adopters among India’s urban population (sometimes obtaining weight-loss injections off-label) have reported success, spurring more inquiries about these treatments. In summary, India’s GLP-1 market, though currently a tiny slice of the global pie, is poised for exciting growth. It offers a clear example of how an emerging market with a massive diabetes burden can rapidly embrace breakthrough therapies – provided affordability and awareness improve. By 2030 and beyond, GLP-1 drugs could become a mainstay in India’s diabetes and obesity management toolkit, driving significant health and business impacts.

Private Market Excitement: Investment Trends and Key Players

The spectacular growth prospects of GLP-1 therapies have not gone unnoticed by private markets. In the past two years, there has been surging interest from venture capital (VC) and private equity (PE) investors in anything related to GLP-1, from biotech startups developing next-generation drugs to healthcare companies delivering weight-loss programs. This rush of capital and entrepreneurial activity is being compared to a “gold rush” in the metabolic health space. Biopharma investment in obesity and diabetes treatments more than tripled between 2023 and 2024, according to industry data . The excitement is driven by the realization that GLP-1 medications represent a huge new market opportunity – potentially $100+ billion in annual sales within a decade – and could fundamentally change how obesity is treated (with knock-on effects on healthcare and even consumer sectors). Below are some key trends and examples illustrating how private investors are jumping in:

• Venture Funding for Weight-Loss Startups: A wave of digital health and telemedicine startups now offers GLP-1-based weight management programs, and many have raised significant funding. For instance, Found, a U.S. telehealth platform for obesity care, reached a valuation of about $600 million in late 2022 . Another startup, Calibrate Health, secured a $100 million Series B round in 2021 to scale up its model of doctor-guided GLP-1 therapy and lifestyle coaching . Similarly, Form Health raised $38 million in mid-2023 for its virtual obesity clinic that can prescribe GLP-1 medications . Even traditional weight-loss companies have pivoted to get in on the trend – WeightWatchers (WW) made headlines by acquiring Sequence, a telehealth service prescribing GLP-1 drugs, for $132 million in 2023 . These investments reflect high confidence that GLP-1-centric care models will draw large consumer demand. In fact, the number of healthcare providers in the U.S. prescribing GLP-1s jumped 228% from 2020 to mid-2023 as new virtual clinics proliferated .
• Private Equity & Strategic Investments: Private equity firms are actively investing in this space, attracted by rapid growth and consolidation opportunities. For example, PE firm Madryn Asset Management acquired a 70% stake in Calibrate in 2022 to fuel its expansion . PE-backed roll-ups of weight-loss clinics and telehealth platforms are emerging, aiming to build nationwide networks that combine GLP-1 prescriptions with diet/lifestyle coaching (a hybrid model that many see as the future of obesity care) . Beyond clinical services, investors are eyeing related sectors – from pharmacies to healthcare IT – that can benefit from the GLP-1 boom. Notably, the prospect of broader insurance coverage for obesity drugs is improving: an estimated 43% of U.S. employers plan to cover GLP-1 weight-loss medications in 2024 (up from 25% in 2023) . If insurance coverage expands, it could massively increase patient access, further enticing private investors to back companies in the delivery chain (specialty pharmacies, benefit coordinators, etc.) that can serve this growing volume of GLP-1 prescriptions.
• Biotech Startups and Big Rounds: On the drug development side, new biotech companies focusing on next-gen GLP-1 analogs or complementary therapies have attracted unprecedented funding. A striking recent example is Verdiva Bio, a U.K.-based obesity biotech that launched in January 2025 with an oversubscribed $411 million Series A financing . This is one of the largest first-round raises for any biotech startup in recent years, giving Verdiva resources to advance a portfolio of oral and long-acting GLP-1 class drugs. Similarly, Kailera Therapeutics emerged from stealth in 2024 with a nearly $400 million financing to develop obesity treatments . These outsized funding rounds underscore how investors expect the next wave of GLP-1 innovations (such as pill formulations, longer-acting injections, or combination drugs like dual agonists) to capture huge markets. Big Pharma is also partnering or acquiring aggressively in this arena – for instance, in late 2023 Roche agreed to acquire GLP-1 developer Carmot Therapeutics for up to $3 billion, aiming to challenge Novo and Lilly’s leadership in weight-loss drugs . While M&A is beyond our main scope here, such deals validate the tremendous commercial potential that private stakeholders see in this field.
• Global and Indian Private Sector Impacts: The GLP-1 frenzy is not limited to the U.S. and Europe. In Europe, a number of startups (e.g. Embla Health in Denmark, Oviva in Switzerland) have begun incorporating GLP-1 prescriptions into their weight-loss programs, though European funding rounds have been more modest so far (often under €10M) . Investors there cite supply shortages and reimbursement hurdles in some countries as factors limiting growth – but interest remains high as these issues get resolved. In China, local biotech firms (like Sciwind Biosciences, which licensed drugs to Verdiva) and healthcare providers are also tapping into the trend, given China’s large diabetic and obese population. Meanwhile in India, the “GLP-1 rush” is taking a slightly different form. Rather than app-based weight-loss startups, Indian private players are mostly pharmaceutical companies positioning to manufacture and sell GLP-1 generics or new formulations, as noted earlier. Major Indian pharma firms (Sun, Biocon, Zydus, Lupin, etc.) see an opportunity to capture domestic market share and even export affordable GLP-1 drugs to other markets once patents expire . This anticipated GLP-1 generic boom has generated optimism among investors in India’s pharma sector. Furthermore, if obesity treatment gains mainstream acceptance in India (potentially with insurance or government program support), we may also see homegrown health-tech startups emerge to serve this segment. For now, the private investment story in India is centered on production and distribution, but the overall excitement is very much aligned with the global trend – GLP-1 therapies are viewed as a game-changing growth avenue in healthcare.

In summary, the GLP-1 industry is experiencing remarkable growth on all fronts. Globally, it is one of the fastest-growing pharmaceutical markets, projected to expand several-fold by 2030 on the back of obesity and diabetes demand . India’s GLP-1 market, though starting small, is set to rise exponentially as local companies and healthcare systems gear up for these therapies . And critically, the innovation and investment pouring in from private markets – billions in venture funding, new startups, and strategic investments – suggest that this boom is only in its early innings. Stakeholders across the board, from global pharma giants to agile startups and investors, are betting that GLP-1 analogs (and future enhancements of this class) will transform the treatment of metabolic disease. If current trends hold, the coming decade could see GLP-1-based treatments become as commonplace as cholesterol or blood-pressure medications, creating immense business opportunities while improving the health of millions worldwide. The excitement in both public and private arenas indicates that the GLP-1 revolution is well underway, and it will be fascinating to watch how this plays out in global markets and in India’s evolving healthcare landscape.

Frequently Asked Questions